A16z unveils $750M fund to bankroll startups at intersection of tech, medicine

microscope
Bio Fund III dwarfs its two predecessors, which totaled $650 million together. (Pixabay)

Four years after Andreessen Horowitz raised its first bio fund, the VC shop is launching its third biotech- and healthcare-focused fund. At $750 million, Bio Fund III is a16z’s biggest fund of its kind yet, and it will bankroll early-stage companies, though General Partner Jorge Conde said it will “selectively” participate in more mature companies, too. 

“We launched our first bio fund about four and a half years ago in recognition of an oncoming trend of biology intersecting with advanced computation in a meaningful way,” Conde told FierceBiotech. “Machine learning and artificial intelligence would have an outsize impact on how we discover drugs and diagnose disease.” 

“And if you look four and a half years hence, to where we are, we think that thesis in very large part has been borne out,” he added. “With Bio Fund III, we recognize that trend has continued: biology, computation and engineering continue to intersect … The technology industry and the healthcare industry continue to merge, blur lines and break down siloes that previously existed.” 

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

RELATED: Bain creates $1.1B fund for fresh round of life science bets 

Bio Fund III dwarfs its two predecessors, which totaled $650 million together. And that’s not all—a16z has built a team around its biotech and healthcare efforts. When it launched the $200 million Bio Fund I, it had one general partner dedicated to those efforts in the form of Vijay Pande, Ph.D. Now, it has four. 

It needs that money and manpower to build a “new breed” of companies that will “attack the most audacious goals in healthcare: using AI to discover new drugs; using data to provide a real-world view into how patients move through our healthcare system; programming our cells to fight disease; improving how we care for our sickest patients; re-engineering the entire process for how we develop, test, and get drugs to patients quickly and at lower cost,” a16z wrote in a blog post Tuesday morning. 

“We wanted to build a bench here not only to cover the broad waterfront, what we see as the opportunity set at these intersections, but also to go very, very deep in evaluating and supporting entrepreneurs building these companies,” Conde said. 

RELATED: Flagship Pioneering adds a new $824M biotech growth fund 

That bench includes Julie Yoo, former vice president of product at Generation Health, and Vineeta Agarwala, M.D., Ph.D., an oncologist who’s also an alum of the Broad Institute, Flatiron Health and GV (formerly Google Ventures). 

The “sweet spot” for Bio Fund III will be seed and series A rounds for early-stage companies, but a16z may occasionally back a series B or even a series C round, Conde explained. As for why this new fund is so much bigger than its predecessors, Conde said the VC firm needed a fund to match the broad opportunity before it—one that includes synthetic biology that doesn’t just play a role in healthcare and human health but also in agriculture, textiles manufacturing and the like. 

A16z expects the “new generation” of companies it backs to become the flagship companies of their space, where biology and technology meet. 

“Over the last decade or so, a new generation of companies emerged where there was an important technological shift—internet, mobile, pick your technology shift,” Conde said. “Those companies grew to be larger and more important companies than people previously anticipated.”

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.